This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.81% per year. These returns cover a period from January 1, 1988 through November 3, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
biotechs: Archive
AcelRx (ACRX) Inks Agreement With Aguettant for Dzuveo in Europe
by Zacks Equity Research
AcelRx (ACRX) enters a licensing agreement for Dzuveo in Europe and an in-licensing agreement for two products in the United States.
RGENPositive Net Change ACRXPositive Net Change ZTSPositive Net Change ACADPositive Net Change
biotechs medical pharmaceuticals
Galapagos (GLPG) Falls on Inflammatory Study Data Readout
by Zacks Equity Research
Galapagos (GLPG) announces data from multiple studies evaluating its two inflammatory candidates - GLPG3970 and GLPG3667. Stock down.
GILDPositive Net Change ALXNPositive Net Change ADPTPositive Net Change GLPGPositive Net Change
biotechs
Axsome (AXSM) Falls 10% After Losing Breakthrough Therapy Tag
by Zacks Equity Research
The FDA rescinds Breakthrough Therapy designation for Axsome's (AXSM) pipeline candidate, AXS-12. The company is developing AXS-12 for the potential treatment of cataplexy in narcolepsy patients.
PFENegative Net Change JAZZPositive Net Change AXSMPositive Net Change HRMYNegative Net Change
biotechs
TFF Pharmaceuticals (TFFP) Completes Enrollment in Phase I Study
by Zacks Equity Research
TFF Pharmaceuticals (TFFP) completes enrollment in the phase I study on tacrolimus inhalation powder and announces positive preliminary data.
BAYRYPositive Net Change HALOPositive Net Change ZTSPositive Net Change TFFPPositive Net Change
biotechs
Biotech Stock Roundup: BIIB & PRTA Provide Updates, CLDX Up on Positive Data & More
by Zacks Equity Research
The biotech sector was in focus last week on key updates form Biogen (BIIB) and Prothena (PRTA).
BIIBNegative Net Change NVONegative Net Change AMGNPositive Net Change CLDXNegative Net Change PRTAPositive Net Change
biotechs medical
Celldex (CLDX) Up Almost 40% Since Skin Disorder Study Data
by Zacks Equity Research
Celldex (CLDX) announces 95% response rate in urticaria patients in an early-stage study evaluating a single dose of its antibody candidate, CDX-0159. Shares are up almost 40% since last Friday.
NVSPositive Net Change RHHBYNegative Net Change MRKPositive Net Change CLDXNegative Net Change
biotechs
Can the Rally in HUTCHMED (HCM) Shares Continue?
by Zacks Equity Research
As of late, it has definitely been a great time to be an investor of HUTCHMED (China) Limited (HCM).
HCMNegative Net Change
biotechs medical
Moderna (MRNA) Set to Supply Argentina With COVID-19 Vaccine
by Zacks Equity Research
Moderna (MRNA) signs an agreement with the government of Argentina for supplying 20 million doses of its COVID-19 vaccine, mRNA-1273, or an updated booster vaccine shot, if approved.
JNJNegative Net Change PFENegative Net Change MRNAPositive Net Change BNTXPositive Net Change
biotechs
Aridis' (ARDS) COVID Antibody Combo Neutralizes Delta Variant
by Zacks Equity Research
Aridis Pharmaceuticals' (ARDS) inhaled COVID-19 dual antibody cocktail treatment, AR-712, binds and neutralizes the Delta variant of the virus. Stock rises in after-hours trading.
REGNPositive Net Change LLYPositive Net Change ARDSPositive Net Change VIRNegative Net Change
biotechs
Prothena (PRTA) to Sell ATTR Amyloidosis Program to Novo Nordisk
by Zacks Equity Research
Prothena (PRTA) announces an agreement to sell its clinical-stage antibody, PRX004, and the broader ATTR amyloidosis program for $1.2 billion to Novo Nordisk.
BIIBNegative Net Change RHHBYNegative Net Change NVONegative Net Change PRTAPositive Net Change
biotechs medical
Biogen (BIIB) In-Licenses Rights to Multiple Sclerosis Drug
by Zacks Equity Research
Biogen partners with InnoCare Pharma for orelabrutinib, a BTK inhibitor with the potential of treating multiple sclerosis. The drug is currently undergoing phase II study.
BIIBNegative Net Change ALXNPositive Net Change BAYRYPositive Net Change RGENPositive Net Change
biotechs
Sigilon (SGTX) Down as FDA Places Hold on Hemophilia Study
by Zacks Equity Research
Sigilon (SGTX) stock declines as the FDA puts a clinical hold on its early/mid-stage hemophilia A study that was evaluating its lead candidate SIG-001.
RHHBYNegative Net Change NVONegative Net Change ZTSPositive Net Change
biotechs medical pharmaceuticals
Seagen (SGEN) Gets Regular Approval, Label Expansion for Padcev
by Zacks Equity Research
Seagen and Astellas' two sBLAs for Padcev get FDA approval for patients with locally advanced or metastatic urothelial cancer. The approval comes one month before the PDUFA date of Aug 17, 2021.
MRKPositive Net Change BAYRYPositive Net Change SGENPositive Net Change BNTXPositive Net Change
biotechs
Do Options Traders Know Something About IVERIC bio (ISEE) Stock We Don't?
by Zacks Equity Research
Investors need to pay close attention to IVERIC bio (ISEE) stock based on the movements in the options market lately.
ISEEPositive Net Change
biotechs medical
A Comprehensive Guide to Genomic ETFs
by Sweta Jaiswal, FRM
Genomic ETFs are expected to benefit from the favorable trends in the genomic editing space.
BEAMPositive Net Change EDITPositive Net Change PBENegative Net Change NTLAPositive Net Change CRSPPositive Net Change ARKGPositive Net Change GNOMPositive Net Change IDNANo Net Change
biotechs etfs genetics
Bristol-Myers (BMY) Gains 7.6% YTD: What to Expect in 2H
by Zacks Equity Research
Bristol-Myers (BMY) maintains momentum on new drug approvals despite some key established drugs facing challenges.
BMYNegative Net Change PFENegative Net Change RGENPositive Net Change
biotechs pharmaceuticals
F-star (FSTX), AstraZeneca Team Up for Novel STING Inhibitors
by Zacks Equity Research
F-star partners with AstraZeneca for its novel STING inhibitor compounds. Resultantly, F-star's shares rise 9.1%.
AZNNegative Net Change BAYRYPositive Net Change BNTXPositive Net Change
biotechs
BioNTech (BNTX)/ Pfizer to Seek FDA Nod for COVID-19 Booster
by Zacks Equity Research
BioNTech (BNTX) and partner Pfizer plan to get authorization for COVID-19 booster vaccine shot in the United States owing the emerging Delta variant of the virus.
JNJNegative Net Change PFENegative Net Change MRNAPositive Net Change BNTXPositive Net Change
biotechs
Biogen (BIIB) Gets FDA Nod for Narrow Label of Aduhelm
by Zacks Equity Research
The FDA approves label update for Biogen's (BIIB) new Alzheimer's drug, Aduhelm. The updated label narrows the patient population, which is eligible for the drug.
NVSPositive Net Change BIIBNegative Net Change RHHBYNegative Net Change AMGNPositive Net Change
biotechs
Moderna (MRNA) Begins Dosing in Study on mRNA Flu Vaccine
by Zacks Equity Research
Moderna (MRNA) doses the first participant in a phase I/II study on its quadrivalent mRNA-based vaccine candidate, mRNA-1010, against seasonal influenza.
AZNNegative Net Change MRNAPositive Net Change NVAXPositive Net Change BNTXPositive Net Change
biotechs
Amgen (AMGN)/AstraZeneca's Asthma Drug Gets FDA Priority Tag
by Zacks Equity Research
The FDA accepts and grants priority review to Amgen (AMGN)/AstraZeneca's BLA for tezepelumab for the treatment of asthma.
REGNPositive Net Change AZNNegative Net Change GSKPositive Net Change AMGNPositive Net Change
biotechs
Biohaven (BHVN) Q2 Nurtec Preliminary Sales Top Expectations
by Zacks Equity Research
Biohaven Pharmaceutical's (BHVN) sole approved drug, Nurtec ODT's preliminary sales outperform expectations. Resultantly, share increase 13.6%.
BAYRYPositive Net Change RGENPositive Net Change BHVNPositive Net Change BNTXPositive Net Change
biotechs
Vaxart (VXRT) Enters an Agreement With Altesa for Antiviral
by Zacks Equity Research
Vaxart (VXRT) enters a licensing agreement with Altesa Biosciences, Inc., whereby the latter gets rights to develop, manufacture and commercialize vapendavir.
BAYRYPositive Net Change EBSPositive Net Change ZTSPositive Net Change VXRTNegative Net Change
biotechs pharmaceuticals
WHO Guidelines Put Spotlight on Arthritis Drugs Actemra & Kevzara
by Zacks Equity Research
The latest guideline update by the WHO includes the use of arthritis drugs like Roche's (RHHBY) Actemra and Sanofi's (SNY) Kevzara for the treatment of severe COVID-19.
REGNPositive Net Change SNYPositive Net Change RHHBYNegative Net Change LLYPositive Net Change
biotechs pharmaceuticals
Company News for Jul 8, 2021
by Zacks Equity Research
Companies in The News Are: BHVN, MSM, SGH, NKLA
MSMPositive Net Change BHVNPositive Net Change SGHPositive Net Change
auto-tires-trucks biotechs industrial-products semiconductor